The relationship between catastrophizing and altered pain sensitivity in patients with chronic low-back pain

Samantha M. Meints[a,*], Ishtiaq Mawla[b], Vitaly Napadow[a,b], Jian Kong[b,c], Jessica Gerber[b], Suk-Tak Chan[b], Ajay D. Wasan[d], Ted J. Kaptchuk[e], Christina McDonnell[a], Junie Carriere[a], Bruce Rosen[b], Randy L. Gollub[b,c], Robert R. Edwards[a]

Abstract

Changes in central pain processing have been shown in patients with chronic low-back pain (cLBP). We used quantitative sensory testing methods to identify differences in pain sensitization between patients with cLBP (N = 167) and healthy controls (N = 33). Results indicated that, compared with healthy pain-free controls, cLBP patients showed increased sensitivity and greater painful aftersensations for mechanical pressure and pin-prick stimuli and lower tactile spatial acuity in the 2-point discrimination task ($ps < 0.05$). Then, we examined the role of pain catastrophizing as a mediator of the group differences in pain sensitization. We found that catastrophizing partially accounted for group differences in pressure required to produce moderate pain. Finally, we examined the relationship between pain sensitization, catastrophizing, and clinical pain among patients with cLBP. We found that catastrophizing and deep-tissue pressure pain were associated with greater pain intensity in the past month, week, and at the visit as well as low-back pain bothersomeness. Furthermore, deep-tissue pressure pain mediated the associations between catastrophizing and both pain in the past month and low-back pain severity. Taken together, these results indicate that not only do patients with cLBP demonstrate increased pain sensitization and decreased sensitivity to innocuous stimuli, but these changes are also linked with increased catastrophizing. Furthermore, both catastrophizing and sensitization are associated with increased clinical pain among cLBP patients.

Keywords: Chronic low-back pain, Pain sensitization, Catastrophizing, QST

1. Introduction

Chronic low-back pain (cLBP) affects 15% to 30% of the US population[14] and is the leading cause of disability worldwide.[20] Unfortunately, treatment options for cLBP often yield only limited relief. However, the development of more efficacious, better-targeted treatments for cLBP requires a better understanding of the mechanisms that contribute to the onset, maintenance, and impact of this chronic condition.[14]

One proposed mechanism that may contribute to the development and maintenance of cLBP is pain sensitization.[2,11] Pain sensitization involves increased responsiveness of central

and/or peripheral nervous system circuits, resulting in pain hypersensitivity (eg, allodynia and hyperalgesia)[27,62,67] and potentially poor pain-related outcomes (**Fig. 1**).[11] To date, however, there is equivocal evidence for sensitization among patients with cLBP.[59] Some studies have found widespread pain sensitization among patients with cLBP across various pain modalities,[10,22,23,37] whereas other studies show minimal sensory differences between cLBP patients and healthy controls.[34,36,45,52,53] Other studies report mixed findings with cLBP patients demonstrating pain sensitivity for some modalities, but not others.[3,15,38,49] Given the considerable individual differences in pain sensitization even within this disease state, understanding the factors contributing to sensitization and the relationship between pain sensitization and pain-related outcomes is warranted.

A related mechanistic contributor to the experience of cLBP is pain catastrophizing. Pain catastrophizing, a pattern of negative cognitive-emotional responses to pain that includes rumination, magnification, and helplessness,[63] has been shown to be associated with pain severity, disability, and poor outcomes for patients with cLBP.[26,46,48] It has also been shown to predict the development of chronic pain in previously pain-free individuals, and the chronification of acute back pain.[60,68] Pain sensitization and pain catastrophizing may also be inter-related. For example, some previous studies suggest that catastrophizing is a contributor to pain sensitivity through aberrant central nervous system processing of pain-related information.[24,49] However, as noted by Curatolo and Arendt-Nielsen,[11] the role of psychosocial factors, such as catastrophizing, in the development of pain

Figure 1. Curatolo and Arendt-Nielsen (2015) model of path between peripheral injuries, central hypersensitivity, and clinical consequences.

sensitization remains unclear with additional research needed to identify such mechanisms.

Collectively, there is mixed evidence supporting pain sensitization as a pathophysiological mechanism of cLBP. Although the role of catastrophizing as a psychosocial factor contributing to the development of chronic pain and poor pain-related outcomes has been documented, the role of catastrophizing as a mechanism of pain sensitization and the effect of pain sensitization on pain-related outcomes among cLBP patients remain unclear. In the current study, we use a large sample and formal mediation analyses to better understand the relationships between pain sensitization, catastrophizing, and pain outcomes in cLBP. We first aimed to identify differences in pain sensitivity between patients with cLBP and healthy, pain-free controls using quantitative sensory testing (QST) procedures.[2,11] Then, we examined the role of pain catastrophizing as a mediator of the group differences in pain sensitization. Finally, we examined the relationship between pain sensitization, catastrophizing, and clinical pain among patients with cLBP.

2. Methods

2.1. Participants and design

The current study uses only the baseline behavioral and clinical data collected between 2013 and 2017 from a large single-site neuroimaging-based longitudinal treatment study of acupuncture in patients with cLBP (P01-AT006663; clinicaltrials.gov/ct/show/NCT01614639). Upon arrival at the laboratory, participants provided informed consent. They then completed a series of baseline questionnaires assessing their demographic information, pain, depression, and catastrophizing. Participants subsequently underwent QST as described below. Upon completion of the study, participants were debriefed and compensated. All procedures were approved by the Partners Healthcare Institutional Review Board.

Participants were 167 adults (age 18-60) with idiopathic cLBP and 33 healthy, pain-free controls. Participants were recruited through e-mail, internet, and bulletin board advertisements in Boston, MA, as well as through electronic medical records–based databases from Brigham and Women's and Massachusetts General Hospitals. All participants, both those with cLBP and healthy controls, were included if they were right-handed, acupuncture-naive, and were able to complete self-report measures of pain, psychosocial functioning, and medical history. Potential participants from either group (cLBP or healthy controls) were excluded if (1) they had a history of cardiac, respiratory, or nervous system disease that may impact MRI, (2) acupuncture or MRI were contraindicated, (4) they had systemic diseases, (5) they had a history of head injury or coma, or (6) they had active substance abuse disorder within the past 2 years. Inclusion criteria for patients with cLBP required (1) meeting Quebec Task Force Classifications System symptom categories I-II (ie, unlikely to have significant nerve root involvement, stenosis, or mechanical instability [Abenhaim et al., 2000; Loisel et al., 2002]) diagnosed by a clinical evaluation including the use of X-ray/MRI reports when available, (2) low-back pain duration greater than 6 months, (3) average low-back pain intensity rating ≥ 4 on a 0 to 10 numeric rating scale (NRS) (0: no pain, 10: most intense pain imaginable) over the 2-week period before enrollment, and (5) the ability to temporarily exacerbate cLBP with calibrated physical maneuvers. Patients with cLBP were excluded if (1) back pain manifested with one or more specific causes (eg, cancer, fracture, and infection), (2) radicular pain radiated below the knee, (3) back problems were complicated (eg, medicolegal issues), (4) they had undergone previous back surgery, or (5) they were on daily high-dose opioids (> 60-mg morphine equivalents [MME]).

2.2. Measures

The Pain Catastrophizing Scale[63] is a 13-item self-report measure of pain-related catastrophizing comprising rumination, magnification, and helplessness.[12,51] To complete this measure, participants were asked to identify how frequently they experience catastrophic cognitions in response to pain using a scale from 0 (not at all) to 4 (all the time). Item scores were then summed to determine an aggregate score of pain catastrophizing. The Pain Catastrophizing Scale has been shown to be valid and reliable among patients with chronic pain.[66]

The Beck Depression Inventory-II (BDI-II)[4] is a 21-item self-report measure of depressive symptoms. Participants rated the severity with which they experienced depressive symptoms over the past 2 weeks on a scale from 0 (not present) to 3 (severe). Item scores were then summed to determine an aggregate score of depressive symptoms. The BDI-II has been validated among patients with chronic pain.[25]

Low-back pain bothersomeness was assessed only in the cLBP group with a single-item question asking, "How bothersome has your low back pain been during the past week?" Participants rated the bothersomeness of their back pain on a 0 to 10 visual analog scale ranging from "not at all bothersome" to "extremely bothersome." This widely accepted assessment has been shown to be both valid and reliable.[5,8,13] Average pain intensity in the past week and month was assessed using a 11-point NRS ranging from 0 (no pain) to 10 (worst pain imaginable). Pain at the beginning of the visit was rated on a 0 to 100 NRS ranging from "no pain" to "worst pain imaginable." The NRS has been validated for specificity and use in chronic pain research.[21,28] Pain interference was assessed using the pain interference items from the Patient-Reported Outcomes Measurement Information System (PROMIS-29).[1] Pain duration was also measured in years.

2.3. Quantitative sensory testing

2.3.1. Two-point discrimination

Two-point discrimination thresholds are a measure of tactile acuity for nonpainful mechanical sensation.[31,33] Using a 2-point aesthesiometer (Mitutoyo Digital Caliper, Mitutoyo), subjects completed a series of ascending and descending trials in which they indicated whether they felt "1 distinct point" or "2 points separated by a distance." This task was performed at 2 body sites: the right side of the lower back (over the erector spinae muscles, medial to PSIS, and level with the lumbar vertebrae) and the right index finger (middle phalanx and palmar surface). Participant eyes were closed throughout the testing session and finger testing followed back testing. The right index finger served as a "control" body site to the lower back (affected body site due to pain pathology). For stimulations after a descending order, the experimenter started with a large separation distance and decreased the distance every 3 stimulation trials (distance was decreased by 1 cm for the lower back and 1 mm for the index finger). After every 3 stimulation trials at a particular separation distance, the experimenter verbally asked the participant if they felt 1 or 2 points. The separation distance at which 2 points shifted to 1 point was repeated twice and if subject reported the change consistently, the distance was recorded. The same procedure was repeated with the ascending order, but the starting separation distance was zero and gradually increased from that distance. Ascending and descending order administration was counterbalanced across subjects. Results of the ascending and descending orders were then averaged to determine the 2-point discrimination threshold for each body site.

2.3.2. Deep-tissue pressure pain

Cuff pressure algometry was used to determine responses to deep pressure pain.[17,32,41,55] Using a Hokanson rapid cuff inflator, tonic, deep-tissue, mechanical stimulation was applied to the left gastrocnemius muscle using a standard blood pressure cuff. To begin, the cuff was inflated to 30 mm Hg, a nonpainful pressure for all participants, which was verbally confirmed by the experimenter. Using a method of limits, the cuff pressure was increased at a rate of approximately 5 mm Hg per second. The experimenter asked the participant to provide a verbal prompt when the stimulus first transitioned from being nonpainful to painful. When the participant prompted the experimenter that the stimulus became painful, the experimenter increased cuff pressure in steps of 15 mm Hg. At each 15 mm Hg increase, the participant provided a verbal rating of pain intensity and unpleasantness from 0 (no pain; not at all unpleasant) to 100 (worst pain imaginable; most unpleasant imaginable). When pain intensity reached a level of ~40/100, the experimenter recorded the pressure in mm Hg (P40) and kept that pressure level constant for the remainder of the experiment. This P40 was the target pressure also used as a metric of pain sensitivity. At this steady P40 pressure, the participant provided verbal ratings of pain and unpleasantness every 30 seconds for 2 minutes. After 2 minutes, the cuff was deflated. Fifteen seconds after cuff deflation, participants provided verbal ratings of any painful aftersensations.[61] The mean ratings were calculated by averaging the 30, 60, 90, and 120 ratings separately for pain intensity and pain unpleasantness. Participants were unable to see the display on the Hokanson rapid cuff inflator device to minimize any anchoring effects in pain/unpleasantness ratings.

2.3.3. Mechanical punctate pain

Mechanical punctate pain was assessed using weighted pinprick stimulators.[16,17,19] Participants used a 0 (no pain) to 100 (worst pain imaginable) NRS to rate the sensation of pain produced by 64 mN, 128 mN, and 256 mN stimulators. The lowest force stimulator that produced a painful sensation (128 or 256 mN for most participants) was then used to apply a train of 10 stimuli to the skin on the dorsum of the right middle finger (middle phalanx) at a rate of 1 pinprick per second. Participants provided pain ratings for the first, fifth, and 10th stimulus. Fifteen seconds after the end of the stimulus train, participants rated painful aftersensations on the same 0 to 100 scale.[18,19] To calculate temporal summation, the pain intensity rating after the first stimulus was subtracted from the rating after the 10th stimulus. The pain ratings from the initial 3 stimulators (64 mN, 128 mN, and 256 MN) were averaged to determine mean mechanical punctate pain intensity.

2.4. Data analysis

2.4.1. Differences between chronic low-back pain and HC groups

We used independent sample t tests and χ^2 analyses to determine differences in demographic variables and pain variables between the cLBP and HC groups. We ran independent samples t tests to identify differences between cLBP and HC groups on the following QST outcomes: 2-point discrimination on the finger, 2-point discrimination on the back, P40 pressure, mean deep-tissue cuff pressure pain intensity, mean deep-tissue cuff pressure pain unpleasantness, deep-tissue cuff pressure painful aftersensations, pain rating for first mechanical punctate stimulus, pain rating for 10th mechanical punctate stimulus, mean pain ratings for pinprick probes, temporal summation of mechanical punctate pain, and mechanical punctate painful aftersensations. We then examined the relationship between catastrophizing and QST outcomes in the entire sample using Pearson correlations. Finally, using the Process Macro for SPSS,[56,57] we conducted bias-corrected

Table 1

Participant characteristics.

Characteristics	HC (n = 33)	CLBP (n = 167)	t or χ^2 statistic
Age, mean (SD)	43.35 (10.84)	40.77 (12.29)	1.22
Sex, n (%)			0.14
Male	15 (45)	70 (42)	
Female	18 (55)	97 (58)	
Race, n (%)			2.62
American Indian/Alaska Native	0 (0)	1 (<1)	
Asian	2 (6)	8 (5)	
Native Hawaiian or other Pacific Islander	0 (0)	1 (<1)	
Black or African American	4 (12)	17 (10)	
White	26 (79)	122 (73)	
More than one race	1 (3)	12 (7)	
Unknown	0 (0)	6 (4)	
Opioid use, n (%)			4.97*
Yes	0 (0)	22 (13)	
Depression, mean (SD)	1.7 (3.7)	6.6 (6.8)	−5.77**
Pain in the past month, mean (SD)	0.1 (0.4)	5.9 (1.8)	−36.39**
Pain in the past week, mean (SD)	0.2 (0.9)	5.6 (1.7)	−27.10**
Pain at visit, mean (SD)	0.3 (1.7)	43.4 (21.7)	−25.27**
Low-back pain bothersomeness, mean (SD)	—	6 (2)	—
Pain interference, mean (SD)	—	11 (4)	—
Pain duration in years, mean (SD)	—	8 (7)	—
Catastrophizing, mean values (SD)	3 (5)	13 (9)	−8.95**

**$P < 0.01$; *$P < 0.05$.
CLBP, chronic low-back pain; HC, healthy pain-free control.

bootstrapped mediation analyses using 10,000 bootstrapped resamples to examine the role of catastrophizing as a potential mediator of the group differences in QST responses controlling for depression and opioid use.[56,57] Bootstrapping is a non-parametric procedure that does not assume indirect effects are normally distributed. For these analyses, we only conducted mediation models for QST variables when (1) there were significant group differences in the QST response and (2) the QST response was significantly correlated with catastrophizing ($P < 0.05$). Estimates of indirect effects were considered significant in the case that zero was not included in the 95% confidence intervals.[56,57]

2.4.2. Associations between catastrophizing, pain outcomes, and quantitative sensory testing in chronic low-back pain patients

To examine the associations between catastrophizing, pain outcomes, and QST variables, we first conducted Pearson correlations within the cLBP sample. We then conducted bias-corrected bootstrapped multiple mediation analyses using 10,000 bootstrapped resamples to examine the role of pain sensitization (as measured by QST) as mediators of the relationship between catastrophizing and clinical pain outcomes controlling for depression and opioid use. For these analyses, we only restricted QST variables to only those correlated with both catastrophizing and pain outcomes ($P < 0.05$); likewise, we restricted outcome variables to only those correlated with both catastrophizing and QST variables ($P < 0.05$). Again, estimates of indirect effects were considered significant in the case that zero was not included in the confidence intervals.[56,57] All statistical analysis was conducted using SPSS 24 (Chicago, IL).

3. Results

3.1. Participant characteristics

The sample consisted of 200 participants in total (167 cLBP; **Table 1**). There were no significant differences between the groups with respect to age, sex, or race. Compared with healthy controls (who did not use opioid pain medications), approximately 16% of cLBP patients used them ($\chi^2_1 = 4.97$, $P < 0.05$). Patients with cLBP also reported greater overall depressive symptoms ($t_{198} = -5.77$, $P < 0.01$) and pain catastrophizing ($t_{80.8} = -8.95$, $P < 0.01$).

3.2. Quantitative sensory testing differences between HC and chronic low-back pain groups

Results of a series of independent sample t tests comparing pain sensitivity between patients with cLBP and healthy controls indicated significant differences across several QST modalities (**Table 2**). Patients with cLBP demonstrated lower spatial acuity in the low-back area ($t_{195} = -2.26$, $P < 0.05$) compared with healthy controls; however, there were no differences in spatial acuity at the finger, a pain-free control site (ie, finger; $P > 0.05$). Compared with healthy controls, cLBP patients required less cuff inflation pressure to produce moderate deep-tissue pain (P40; $t_{198} = 2.83$, $P < 0.01$) and provided higher pain intensity ratings for mechanical punctate probes of various forces ($t_{114.3} = -5.91$, $P < 0.01$), offering evidence for hyperalgesia in cLBP patients. Both cLBP patients and healthy controls demonstrated temporal summation of mechanical punctate pain, and there were no group differences in temporal summation. Patients with cLBP did, however, rate aftersensations from the mechanical punctate stimulus as more painful ($t_{64.2} = -2.65$, $P < 0.05$) than their pain-free counterparts.

Table 2

Independent *t* tests for QST Outcomes.

Outcome	Group	Mean	SD	t	d
Two-point discrimination—finger	HC	3.16	1.53	−1.83	0.37
	CLBP	3.78	1.83		
Two-point discrimination—back	HC	34.53	15.42	−2.26*	0.45
	CLBP	41.73	16.69		
P40 pressure	HC	201.94	79.81	2.83**	0.50
	CLBP	165.69	64.66		
Cuff mean pain intensity	HC	44.89	18.73	−1.21	0.21
	CLBP	48.53	15.10		
Cuff mean pain unpleasantness	HC	49.75	21.91	−1.15	0.21
	CLBP	54.27	20.44		
Cuff painful aftersensations	HC	3.85	7.31	−1.66	0.25
	CLBP	6.61	13.90		
1st probe pain rating	HC	10.94	11.85	−1.95	0.40
	CLBP	16.08	13.98		
10th probe pain rating	HC	25.58	25.14	−1.58	0.28
	CLBP	32.05	20.49		
Mean pain rating 64-256 mN probes	HC	3.09	4.56	−5.91**	0.82
	CLBP	10.06	11.11		
Temporal summation of probes	HC	14.64	16.73	−0.40	0.08
	CLBP	15.97	17.57		
Probe painful aftersensations	HC	2.87	7.00	−2.65*	0.43
	CLBP	6.84	10.92		

**P < 0.01; *P < 0.05.
CLBP, chronic low-back pain; QST, quantitative sensory testing.

3.3. Bivariate associations between catastrophizing and quantitative sensory testing responses among all participants

Results of Pearson correlations indicated that greater catastrophizing was associated with decreased spatial acuity on the lower back, as reflected by a larger 2-point discrimination threshold ($r = 0.161$; $P < 0.05$; **Table 3**). Greater catastrophizing was also associated with lower P40 cuff inflation pressure ($r = -0.196$; $P < 0.01$), as well as higher ratings for pressure pain aftersensations ($r = 0.199$; $P < 0.01$) and mean pressure pain unpleasantness ($r = 0.259$; $P < 0.01$).

3.4. Catastrophizing as a mediator of group differences in quantitative sensory testing

As indicated in the analysis section, mediation analyses were only conducted: (1) there were significant group differences in the QST response (ie, low-back spatial acuity, P40 pressure, mean mechanical punctate pain ratings, and mechanical painful aftersensations) and (2) the QST response was significantly correlated with catastrophizing (low-back spatial acuity, P40 pressure, and average pressure pain unpleasantness and aftersensations). This resulted in mediation analyses for low-back spatial acuity and P40 pressure. Results of the first mediation analysis indicated that catastrophizing accounted for 23% of the variance in P40 cuff inflation pressure and significantly mediated the group differences in P40 cuff inflation pressure. Patients with cLBP endorsed higher levels of catastrophizing, which were associated with requiring less pressure to produce moderate deep-tissue pain (**Fig. 2**). Catastrophizing did not mediate the group differences in low-back spatial acuity (CI includes 0).

3.5. Relationships between catastrophizing, pain outcomes, and quantitative sensory testing in chronic low-back pain participants

Results of Pearson correlations used to examine the relationships between catastrophizing, clinical pain outcomes, and QST variables within the cLBP group indicated that greater catastrophizing was associated with pain in the past month ($r = 0.359$, $P < 0.01$), pain in the last week ($r = 0.407$; $P < 0.01$), pain at the visit ($r = 0.333$, $P < 0.01$), low-back pain bothersomeness ($r = 0.429$, $P < 0.01$), and pain interference ($r = 0.521$, $P < 0.01$; **Table 4**). Within the cLBP group, greater catastrophizing was also associated with lower P40 cuff inflation pressure ($r = -0.152$, $P < 0.05$) and greater pressure pain unpleasantness ($r = 0.256$, $P < 0.01$) and aftersensations ($r = 0.188$, $P < 0.05$). Lower P40 cuff inflation pressure was associated with greater pain in the past month ($r = -0.215$, $P < 0.01$), pain in the past week ($r = -0.163$, $P < 0.05$), pain at the visit ($r = -0.233$, $P < 0.01$), and back pain bothersomeness ($r = -0.221$, $P < 0.01$). Furthermore, greater pain in the past month was associated with greater painful pressure aftersensations ($r = 0.246$, $P < 0.01$), whereas greater pain the last week was associated with greater pressure pain unpleasantness ($r = 0.164$, $P < 0.05$). We conducted mediation analyses only when relationships between catastrophizing and pain outcomes (ie, pain in the last month, pain in the last week, pain at the visit, pain bothersomeness, and pain interference), catastrophizing and QST (ie, P40 pressure and pressure pain unpleasantness and aftersensations), and QST and pain outcomes (ie, P40 with pain in the past month, pain in the past week pain at the visit, and pain bothersomeness; pressure pain unpleasantness and pain in the last week; and pressure pain aftersensations and pain in the past month) were all significant ($P < 0.05$). Thus, we ran 4 separate models. In the first model,

4. Discussion

In the current study, we examined the association between 2 key putative contributors to cLBP: pain sensitization and pain catastrophizing. We found that patients with cLBP demonstrated increased pain sensitivity compared with healthy, pain-free controls for various somatosensory measures, and that catastrophizing partially mediated the group differences in the pressure necessary to produce moderate deep-tissue pain. In addition, we found that greater catastrophizing was associated with both experimental pain sensitivity and clinical pain among patients with cLBP, with deep-tissue hyperalgesia mediating the relationship between catastrophizing and clinical pain among cLBP patients.

Consistent with our hypothesis, we found that patients with cLBP demonstrated greater deep-tissue hyperalgesia and increased sensitivity for mechanical punctate pain compared with pain-free controls. Although previous studies have reported that cLBP patients exhibit increased pain sensitivity compared with pain-free controls,[23,30,49,50,58] there is considerable heterogeneity in both the QST methodology used in these studies and the nature of their findings. For example, Giesecke et al.[23] found that pressure pain thresholds on the thumb were greater among cLBP patients compared with healthy controls. On the other hand, O'Neill et al.[49] found that pressure pain thresholds differed between groups only on the infraspinatus muscle (ie, shoulder) but not the tibialis anterior (ie, shin) but also that cLBP patients exhibited higher pain intensity of longer duration for saline-induced muscle pain. This study builds upon previous work by using novel methodology (eg, cuff pressure algometry) while also assessing a variety of QST outcomes to highlight individual differences in pain sensitization while still demonstrating a general pattern of increased sensitization among cLBP patients.

In addition to group differences in pain sensitization, we found that, compared with pain-free controls, cLBP patients demonstrated decreased spatial acuity for an innocuous somatosensory stimulus at the pain site (ie, back) but not at a nonpainful control site (ie, finger). This aligns with previous findings[43,47] suggesting an impairment in somatosensory processing at the site of back pain. There were no differences in the spatial acuity at the hand, signifying that spatial acuity may be pain site-specific and possibly not global in cLBP patients. However, it is important to note that there was a small to moderate effect size for spatial acuity on the hand. Thus additional research is warranted to better characterize somatosensory perception, especially for non-noxious stimuli,

Pearson correlations between catastrophizing and QST measurements in entire sample.

	Catastrophizing
Two-point discrimination—finger	0.078
Two-point discrimination—back	0.161*
P40 pressure	−0.196**
Cuff mean pain intensity	0.120
Cuff mean pain unpleasantness	0.259**
Cuff painful aftersensations	0.199**
1st probe pain rating	0.129
10th probe pain rating	0.077
Pain rating 64-256 mN probes	0.122
Temporal summation of probes	−0.007
Probe painful aftersensations	0.134

**$P < 0.01$; *$P < 0.05$.
QST, quantitative sensory testing.

P40 cuff inflation pressure and ratings of pressure pain aftersensations jointly accounted for 19% of the variance in self-reported pain in the past month. However, only P40 cuff inflation pressure mediated the relationship between catastrophizing and pain in the past month. That is, individuals who endorse greater catastrophizing also demonstrate deep-tissue hyperalgesia, which is associated with greater self-reported pain in the past month (**Fig. 3**). In the second model, cuff inflation pressure accounted for 11% of the variance in pain rating at the time of the visit and significantly mediated the relationship between catastrophizing and pain at the time of the visit (**Fig. 4**). Greater catastrophizing was associated with lower P40 cuff inflation pressure, which, in turn, accounted for greater pain ratings at the time of the visit. In the third model, cuff inflation pressure accounted for 9% of the variance in low-back pain bothersomeness and significantly mediated the relationship catastrophizing and low-back pain bothersomeness such that individuals who endorsed greater catastrophizing demonstrated deep-tissue hyperalgesia, which was further associated with greater low-back pain bothersomeness (**Fig. 5**). In the final model, P40 cuff inflation pressure and pressure pain unpleasantness did not mediate the relationship between catastrophizing and pain in the past week.

	Point Estimate	LL 95% CI	UL 95% CI
Total	-39.09	-66.22	-11.97
Direct	-30.05	-58.17	-1.94
Indirect	-9.04	-17.81	-2.51

Catastrophizing

a = 5.85**　　b = -1.54*

CLBP　　c' = -30.05*　　P40 Pressure

CLBP　　c = -39.09**　　P40 Pressure

Figure 2. The mediating effect of catastrophizing in the relationship between back pain and P40 cuff inflation pressure. *$P < 0.05$; **$P < 0.01$.

Table 4

Pearson correlations between clinical outcomes and QST measurements in CLBP participants.

	Sex	Age	Opioid use	Depression	Catastrophizing	Pain in past month	Pain in last week	Pain at visit	LBP bothersomeness	Pain interference	Pain duration
Sex	1	−0.150	−0.097	−0.148	0.015	0.202**	0.140	0.062	0.078	0.004	−0.039
Age	−0.150	1	0.164*	0.094	0.050	0.058	0.022	0.045	−0.014	0.122	0.220**
Opioid use	−0.097	0.164*	1	0.185*	0.236**	0.111	0.155*	0.163*	0.088	0.239**	−0.161*
Depression	−0.148	0.094	0.185*	1	0.547**	0.276**	0.307**	0.252**	0.310**	0.460**	0.014
Catastrophizing	0.015	0.050	0.236**	0.547**	1	0.359**	0.407**	0.333**	0.429**	0.521**	−0.029
Two-point discrimination—finger	0.03	0.120	0.127	0.051	0.053	0.142	0.042	−0.039	0.082	0.076	0.071
Two-point discrimination—back	−0.023	0.172*	0.123	0.129	0.143	0.117	0.072	0.026	0.082	0.145	0.081
P40 pressure	−0.225**	−0.035	0.005	−0.005	−0.152*	−0.215**	−0.163*	−0.233**	−0.221**	0.067	0.067
Cuff mean pain intensity	−0.023	0.066	−0.53	−0.101	0.112	0.153*	0.162*	0.034	0.101	0.022	0.022
Cuff mean pain unpleasantness	0.094	−0.039	−0.093	0.015	0.256**	0.14	0.164*	0.071	0.144	0.023	0.023
Cuff painful aftersensations	0.104	−0.022	−0.072	0.133	0.188*	0.246**	0.15	0.082	0.131	−0.02	−0.02
1st probe pain rating	0.124	−0.169*	−0.078	−0.027	0.102	0.163*	0.078	0.016	0.131	−0.012	−0.004
10th probe pain rating	0.125	−0.205**	−0.129	−0.076	0.054	0.191*	0.116	0.126	0.131	0.19	−0.093
Pain rating 64-256 mN probes	0.092	−0.220**	−0.105	0.057	0.024	0.051	0.051	0.098	−0.005	−0.147	−0.147
Temporal summation of probes	0.046	−0.105	−0.088	−0.067	−0.019	0.095	0.073	0.134	0.119	0.032	−0.105
Probe painful aftersensations	0.144	−0.064	−0.122	−0.050	0.1	0.233**	0.187*	0.078	0.184*	0.045	−0.46

**P< 0.01; *P< 0.05.
CLBP, chronic low-back pain; QST, quantitative sensory testing.

|	Point Estimate	LL 95% CI	UL 95% CI
Total	0.07	0.03	0.10
Direct	0.05	0.02	0.09
Indirect	0.01	0.01	0.03
P40 Pressure	0.01	0.01	0.02
Aftersensations	0.01	-0.01	0.02

Figure 3. The mediating effect of pain sensitization (as measured by P40 cuff inflation pressure and cuff aftersensations) in the relationship between catastrophizing and pain in the past month controlling for opioid use and depression. *P < 0.05; **P < 0.01.

among patients with cLBP. Taken together, these findings suggest that patients with cLBP demonstrate localized hyposensitivity to non-noxious stimuli despite their increased sensitivity to noxious stimuli overall.

Results of the current study also suggest that catastrophizing may play a role in pain sensitization among patients with cLBP. We found that patients with cLBP endorsed greater levels of catastrophizing, with greater catastrophizing accounting for the group differences in deep-tissue hyperalgesia. This finding supports the extant theory suggesting that psychosocial factors such as catastrophizing may serve as a mechanism in central pain sensitization.[9,44] Furthermore, Taub et al.[64] found that experimental manipulation of catastrophizing among women with cLBP was associated with greater pain sensitivity to punctate mechanical pain, as well as mechanical allodynia, lending further support to the hypothesis that catastrophizing may be causally linked to increased pain sensitization. In fact, this association may be supported by increased functional connectivity between the brain's primary somatosensory (S1) cortical representation of the body site for evoked pain and right anterior insula cortex, as

demonstrated by our recent study in chronic musculoskeletal pain patients.[35]

We also sought to examine the relationship between pain sensitization, catastrophizing, and clinical pain outcomes among patients with cLBP. Consistent with previous studies,[7,11,29,42,54] our results indicated that catastrophizing was associated with both pain sensitization and clinical pain outcomes, whereas pain sensitization (ie, deep-tissue hyperalgesia) was also associated with clinical pain outcomes as proposed in Curatolo and Arendt-Nielsen[11] model. Furthermore, the relationships between catastrophizing and clinical pain outcomes were driven, in part, by differences in deep-tissue hyperalgesia. That is, cLBP patients who exhibited greater deep-tissue hyperalgesia also reported greater pain intensity in the past month, pain at the time of the visit, and low-back pain bothersomeness, and these associations partly accounted for the deleterious effect of catastrophizing on back pain intensity and bothersomeness. Although the central nervous system mechanisms supporting these links between catastrophizing and clinical pain are not well understood, our recent study found that engaging in a catastrophizing task


	Point Estimate	LL 95% CI	UL 95% CI
Total	0.60	0.15	1.05
Direct	0.51	0.06	0.96
Indirect	0.09	0.01	0.23

Figure 4. The mediating effect of pain sensitization (as measured by P40 cuff inflation pressure) in the relationship between catastrophizing pain rating at time of visit controlling for opioid use and depression. *P < 0.05; **P < 0.01.

	Point Estimate	LL 95% CI	UL 95% CI
Total	.009	0.04	0.13
Direct	0.08	0.04	0.12
Indirect	0.01	0.01	0.02

P40 Pressure

a = -1.50*

b = -0.01*

Catastrophizing

c' = 0.08**

LBP Bothersomeness

Catastrophizing

c = 0.09**

LBP Bothersomeness

Figure 5. The mediating effect of pain sensitization (as measured by P40 cuff inflation pressure) in the relationship between catastrophizing and low-back pain bothersomeness controlling for opioid use and depression. $*P < 0.05$; $**P < 0.01$.

activates the brain's posterior cingulate cortex, and that greater clinical pain severity was specifically associated with greater activation of the dorsal posterior cingulate cortex.[40]

Collectively, these results support the notion that central sensitization of pain may be one of the mechanisms implicated in the development and maintenance of idiopathic cLBP, and that this sensitization may be partially driven by negative affective and cognitive responses to pain, as instantiated by elevations in pain-related catastrophizing. Moreover, our findings suggest that greater catastrophizing and the resulting pain sensitization are both associated with greater pain intensity and low-back pain bothersomeness among patients with cLBP. These results have important clinical implications for clinicians involved in the management of patients with cLBP. Instead of focusing on localized pain treatment (eg, injections, topical analgesics, and TENS), clinicians may consider targeting systemic sensitization processes through reductions in catastrophizing. Indeed, there is evidence suggesting that Cognitive Behavior Therapy for Pain is effective in reducing catastrophizing, and that these reductions in catastrophizing are associated with reduced pain and improved functioning among patients with chronic pain.[6,39,65]

Several limitations should be considered when interpreting these findings. First, our sample is disproportionally weighted with cLBP patients compared with healthy, pain-free controls. As a result of this numeric imbalance in group sizes, we may have been underpowered to examine the mediation of group differences in pain sensitivity. Despite this reduced power, we found meaningful group differences, which suggest that the magnitude of these differences was considerable. An additional limitation is the cross-sectional nature of this study. As such, a prospective, longitudinal approach should be considered for future studies to examine catastrophizing as a predictor of the development of sensitization before the onset of cLBP. Although we did identify participants using opioids at the time of the study, we did not account for the frequency, dosing, or duration of opioid use. Given concerns with opioid-induced hyperalgesia, future studies should measure more detailed patterns of opioid use. Finally, although pain sensitization at sites distal to the primary source of pain (eg, the back) suggests a central sensitization of pain, future studies should use neuroimaging methodology to better understand the neural mechanisms involved in both catastrophizing and pain sensitization among patients with cLBP.

In conclusion, the current study uses novel QST modalities, a large clinical sample, and formal mediation analysis to provide a better understanding of pain sensitization among patients with cLBP. Not only did patients with cLBP demonstrate increased pain sensitization and decreased spatial acuity, but these somatosensory changes were also linked with increased catastrophizing. Furthermore, both catastrophizing and sensitization were associated with increased clinical pain among cLBP patients. These findings have important clinical implications and provide us with potential treatment targets for patients with cLBP.

Conflict of interest statement

The authors have no conflict of interest to declare.

Acknowledgements

References

[1] Amtmann D, Cook KF, Jensen MP, Chen WH, Choi S, Revicki D, Cella D, Rothrock N, Keefe F, Callahan L, Lai JS. Development of a PROMIS item bank to measure pain interference. PAIN 2010;150:173–82.

[2] Arendt-Nielsen L, Skou ST, Nielsen TA, Petersen KK. Altered central sensitization and pain modulation in the CNS in chronic joint pain. Curr Osteoporos Rep 2015;13:225–34.

[3] Arntz A, Merckelbach H, Peters M, Schmidt A. Chronic low back pain, response specificity and habituation to painful stimuli. J Psychophysiology 1991;5:177–88.

[4] Beck AT, Steer RA, Brown GK. Beck Depression Inventory-ii (bdi-ii). San Antonio, TX: Psychological Corporation, 1996.

[5] Bombardier C. Outcome assessments in the evaluation of treatment of spinal disorders: summary and general recommendations. Spine (Phila Pa 1976) 2000;25:3100–3.

[6] Burns JW, Day MA, Thorn BE. Is reduction in pain catastrophizing a therapeutic mechanism specific to cognitive-behavioral therapy for chronic pain? Transl Behav Med 2012;2:22–9.

[7] Burton AK, Tillotson KM, Main CJ, Hollis S. Psychosocial predictors of outcome in acute and subchronic low back trouble. Spine 1995;20:722–8.

[8] Cherkin DC, Sherman KJ, Avins AL, Erro JH, Ichikawa L, Barlow WE, Delaney K, Hawkes R, Hamilton L, Pressman A, Khalsa PS, Deyo RA. A randomized trial comparing acupuncture, simulated acupuncture, and usual care for chronic low back pain. Arch Intern Med 2009;169:858–66.

[9] Clark J, Nijs J, Yeowell G, Goodwin PC. What are the predictors of altered central pain modulation in chronic musculoskeletal pain populations? A systematic review. Pain Physician 2017;20:487–500.

[10] Clauw DJ, Williams D, Lauerman W, Dahlman M, Aslami A, Nachemson AL, Kobrine AI, Wiesel SW. Pain sensitivity as a correlate of clinical status in individuals with chronic low back pain. Spine 1999;24:2035–41.

[11] Curatolo M, Arendt-Nielsen L. Central hypersensitivity in chronic musculoskeletal pain. Phys Med Rehabil Clin N Am 2015;26:175–84.

[12] D'Eon JL, Harris CA, Ellis JA. Testing factorial validity and gender invariance of the pain catastrophizing scale. J Behav Med 2004;27:361–72.

[13] Deyo RA, Battie M, Beurskens AJ, Bombardier C, Croft P, Koes B, Malmivaara A, Roland M, Von Korff M, Waddell G. Outcome measures for low back pain research. A proposal for standardized use. Spine 1998;23:2003–13.

[14] Deyo RA, Mirza SK, Martin BI. Back pain prevalence and visit rates: estimates from US national surveys, 2002. Spine (Phila Pa 1976) 2006;31:2724–7.

[15] Diers M, Koeppe C, Diesch E, Stolle AM, Hölzl R, Schiltenwolf M, van Ackern K, Flor H. Central processing of acute muscle pain in chronic low back pain patients: an EEG mapping study. J Clin Neurophysiol 2007;24:76–83.

[16] Edwards RR, Cahalan C, Calahan C, Mensing G, Smith M, Haythornthwaite JA. Pain, catastrophizing, and depression in the rheumatic diseases. Nat Rev Rheumatol 2011;7:216–24.

[17] Edwards RR, Dolman AJ, Michna E, Katz JN, Nedeljkovic SS, Janfaza D, Isaac Z, Martel MO, Jamison RN, Wasan AD. Changes in pain sensitivity and pain modulation during oral opioid treatment: the impact of negative affect. Pain Med 2016;17:1882–91.

[18] Edwards R, Grace E, Peterson S, Klick B, Haythornthwaite J, Smith M. Sleep continuity and architecture: associations with pain-inhibitory processes in patients with temporomandibular joint disorder. Eur J Pain 2009;13:1043–7.

[19] Edwards RR, Wasan AD, Bingham CO, Bathon J, Haythornthwaite JA, Smith MT, Page GG. Enhanced reactivity to pain in patients with rheumatoid arthritis. Arthritis Res Ther 2009;11:R61.

[20] Ehrlich GE. Low back pain. Bull World Health Organ 2003;81:671–6.

[21] Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. PAIN 2001;94:149–58.

[22] Giesbrecht RJ, Battié MC. A comparison of pressure pain detection thresholds in people with chronic low back pain and volunteers without pain. Phys Ther 2005;85:1085–92.

[23] Giesecke T, Gracely RH, Grant MA, Nachemson A, Petzke F, Williams DA, Clauw DJ. Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum 2004;50:613–23.

[24] Gracely RH, Geisser ME, Giesecke T, Grant MA, Petzke F, Williams DA, Clauw DJ. Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain 2004;127:835–43.

[25] Harris CA, Joyce L. Psychometric properties of the Beck Depression Inventory-(BDI-II) in individuals with chronic pain. PAIN 2008;137:609–22.

[26] Henschke N, Maher CG, Refshauge KM, Herbert RD, Cumming RG, Bleasel J, York J, Das A, McAuley JH. Prognosis in patients with recent onset low back pain in Australian primary care: inception cohort study. BMJ 2008;337:a171.

[27] Hestbaek L, Leboeuf-Yde C, Manniche C. Low back pain: what is the long-term course? A review of studies of general patient populations. Eur Spine J 2003;12:149–65.

[28] Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N, Kaasa S. Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage 2011;41:1073–93.

[29] Hübscher M, Moloney N, Leaver A, Rebbeck T, McAuley JH, Refshauge KM. Relationship between quantitative sensory testing and pain or disability in people with spinal pain—a systematic review and meta-analysis. PAIN 2013;154:1497–504.

[30] Jensen OK, Nielsen CV, Stengaard-Pedersen K. Low back pain may be caused by disturbed pain regulation. Eur J Pain 2010;14:514–22.

[31] Jerosch-Herold C. Assessment of sensibility after nerve injury and repair: a systematic review of evidence for validity, reliability and responsiveness of tests. J Hand Surg Am 2005;30:252–64.

[32] Jespersen A, Dreyer L, Kendall S, Graven-Nielsen T, Arendt-Nielsen L, Bliddal H, Danneskiold-Samsoe B. Computerized cuff pressure algometry: a new method to assess deep-tissue hypersensitivity in fibromyalgia. PAIN 2007;131:57–62.

[33] Johansson RS, Vallbo AB. Spatial properties of the population of mechanoreceptive units in the glabrous skin of the human hand. Brain Res 1980;184:353–66.

[34] Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. PAIN 2005;114:295–302.

[35] Kim J, Loggia ML, Cahalan CM, Harris RE, Beissner F, Garcia RG, Kim H, Barbieri R, Wasan AD, Edwards RR, Napadow V. The somatosensory link in fibromyalgia: functional connectivity of the primary somatosensory cortex is altered by sustained pain and is associated with clinical/autonomic dysfunction. Arthritis Rheumatol 2015;67:1395–405.

[36] Kobayashi Y, Kurata J, Sekiguchi M, Kokubun M, Akaishizawa T, Chiba Y, Konno SI, Kikuchi SI. Augmented cerebral activation by lumbar mechanical stimulus in chronic low back pain patients: an FMRI study. Spine (Phila Pa 1976) 2009;34:2431–6.

[37] Laursen BS, Bajaj P, Olesen AS, Delmar C, Arendt-Nielsen L. Health related quality of life and quantitative pain measurement in females with chronic non-malignant pain. Eur J Pain 2005;9:267.

[38] Lautenbacher S, Galfe G, Karlbauer G, Möltner A, Strian F. Effects of chronic back pain on the perception of experimental heat pain. Percept Mot Skills 1990;71(3 suppl):1283–92.

[39] Lazaridou A, Kim J, Cahalan CM, Loggia ML, Franceschelli O, Berna C, Schur P, Napadow V, Edwards RR. Effects of cognitive-behavioral therapy (CBT) on brain connectivity supporting catastrophizing in fibromyalgia. Clin J Pain 2017;33:215–21.

[40] Lee J, Protsenko E, Lazaridou A, Franceschelli O, Ellingsen DM, Mawla I, Isenburg K, Berry MP, Galenkamp L, Loggia ML. Encoding of self-referential pain catastrophizing in posterior cingulate cortex in fibromyalgia. Arthritis Rheumatol 2018;70:1308–18.

[41] Lemming D, Graven-Nielsen T, Sörensen J, Arendt-Nielsen L, Gerdle B. Widespread pain hypersensitivity and facilitated temporal summation of deep tissue pain in whiplash associated disorder: an explorative study of women. J Rehabil Med 2012;44:648–57.

[42] Linton SJ. Do psychological factors increase the risk for back pain in the general population in both a cross-sectional and prospective analysis? Eur J Pain 2005;9:355.

[43] Luomajoki H, Moseley GL. Tactile acuity and lumbopelvic motor control in patients with back pain and healthy controls. Br J Sports Med 2011;45:437–40.

[44] Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol 2007;26:465–73.

[45] Meeus M, Roussel NA, Truijen S, Nijs J. Reduced pressure pain thresholds in response to exercise in chronic fatigue syndrome but not in chronic low back pain: an experimental study. J Rehabil Med 2010;42:884–90.

[46] Mok LC, Lee IF. Anxiety, depression and pain intensity in patients with low back pain who are admitted to acute care hospitals. J Clin Nurs 2008;17:1471–80.

[47] Moseley GL. I can't find it! Distorted body image and tactile dysfunction in patients with chronic back pain. PAIN 2008;140:239–43.

[48] Nicholas MK, Linton SJ, Watson PJ, Main CJ. Early identification and management of psychological risk factors ("yellow flags") in patients with low back pain: a reappraisal. Phys Ther 2011;91:737–53.

[49] O'Neill S, Manniche C, Graven-Nielsen T, Arendt-Nielsen L. Generalized deep-tissue hyperalgesia in patients with chronic low-back pain. Eur J Pain 2007;11:415–20.

[50] O'Neill S, Manniche C, Graven-Nielsen T, Arendt-Nielsen L. Association between a composite score of pain sensitivity and clinical parameters in low-back pain. Clin J Pain 2014;30:831–8.

[51] Osman A, Barrios FX, Gutierrez PM, Kopper BA, Merrifield T, Grittmann L. The Pain Catastrophizing Scale: further psychometric evaluation with adult samples. J Behav Med 2000;23:351–65.

[52] Peters ML, Schmidt AJ. Differences in pain perception and sensory discrimination between chronic low back pain patients and healthy controls. J Psychosom Res 1992;36:47–53.

[53] Peters ML, Schmidt AJ, Van den Hout MA. Chronic low back pain and the reaction to repeated acute pain stimulation. PAIN 1989;39:69–76.

[54] Picavet HS, Vlaeyen JW, Schouten JS. Pain catastrophizing and kinesiophobia: predictors of chronic low back pain. Am J Epidemiol 2002;156:1028–34.

[55] Polianskis R, Graven-Nielsen T, Arendt-Nielsen L. Spatial and temporal aspects of deep tissue pain assessed by cuff algometry. PAIN 2002;100:19–26.

[56] Preacher KJ, Hayes AF. SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res Methods Instrum Comput 2004;36:717–31.

[57] Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods 2008;40:879–91.

[58] Puta C, Schulz B, Schoeler S, Magerl W, Gabriel B, Gabriel HH, Miltner WH, Weiss T. Somatosensory abnormalities for painful and innocuous stimuli at the back and at a site distinct from the region of pain in chronic back pain patients. PLoS One 2013;8:e58885.

[59] Roussel NA, Nijs J, Meeus M, Mylius V, Fayt C, Oostendorp R. Central sensitization and altered central pain processing in chronic low back pain: fact or myth? Clin J Pain 2013;29:625–38.

[60] Salter MW. Cellular neuroplasticity mechanisms mediating pain persistence. J Orofac Pain 2004;18:318–24.

[61] Schreiber KL, Loggia ML, Kim J, Cahalan CM, Napadow V, Edwards RR. Painful after-sensations in fibromyalgia are linked to catastrophizing and differences in brain response in the medial temporal lobe. J Pain 2017;18: 855–67.

[62] Sörensen J, Graven-Nielsen T, Henriksson KG, Bengtsson M, Arendt-Nielsen L. Hyperexcitability in fibromyalgia. J Rheumatol 1998;25:152–5.

[63] Sullivan M, Bishop S, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess 1995;7:524–32.

[64] Taub CJ, Sturgeon JA, Johnson KA, Mackey SC, Darnall BD. Effects of a pain catastrophizing induction on sensory testing in women with chronic low back pain: a pilot study. Pain Res Manag 2017;2017:7892494.

[65] Thorn BE, Burns JW. Common and specific treatment mechanisms in psychosocial pain interventions: the need for a new research agenda. PAIN 2011;152:705–6.

[66] Van Damme S, Crombez G, Bijttebier P, Goubert L, Van Houdenhove B. A confirmatory factor analysis of the Pain Catastrophizing Scale: invariant factor structure across clinical and non-clinical populations. PAIN 2002; 96:319–24.

[67] Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. PAIN 2011;152(3 suppl):S2–15.

[68] Yarnitsky D, Crispel Y, Eisenberg E, Granovsky Y, Ben-Nun A, Sprecher E, Best LA, Granot M. Prediction of chronic post-operative pain: pre-operative DNIC testing identifies patients at risk. PAIN 2008; 138:22–8.